Rapport Therapeutics presented novel findings at the American Epilepsy Society (AES) Annual Meeting, demonstrating a consistent association between decreases in RNS-measured Long Episodes (LEs) and meaningful reductions in clinical seizures. A post-hoc analysis revealed that a 30% reduction in LE frequency correlated with a 50% or greater reduction in clinical seizures. This data validates the LE biomarker for use in proof-of-concept studies.
The change in LE frequency is the primary endpoint for Rapport's ongoing Phase 2a proof-of-concept trial of RAP-219 in focal epilepsy. The validation of this objective biomarker provides a consistent metric to inform the development of future treatments and is expected to enable a more precise and expedited development path for RAP-219. Topline data from this Phase 2a trial is anticipated in mid-2025.
Additional data presented by Rapport at the AES Annual Meeting included preclinical seizure data and Phase 1 pharmacokinetic and safety trial results for RAP-219. These findings collectively support the potential of RAP-219 as a transformative treatment for patients with focal epilepsy, reinforcing the company's precision medicine approach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.